Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff at Meripustak

Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff

Books from same Author: Anamika Bhattacharyya and Nilu Jain and More

Books from same Publisher: BMC Dermatology

Related Category: Author List / Publisher List


  • Price: ₹ 0.00/- [ 0.00% off ]

    Seller Price: ₹ 0.00

Sold By: Machwan      Click for Bulk Order

Offer 1: Get 0.00 % + Flat ₹ 75 discount on shopping of ₹ 500 [Use Code: MPSTK75]

Offer 2: Get 0.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 0.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Shipping charge ₹ 75 for orders below 500



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Anamika Bhattacharyya and Nilu Jain and More
    PublisherBMC Dermatology
    ISBN5-16
    LanguageEnglish
    Publish YearSeptember 2016

    Description

    BMC Dermatology Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff by Anamika Bhattacharyya and Nilu Jain and More

    Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff

    Abstract
    Background

    Dandruff is a common scalp condition characterized by excessive scaling and itch. Aberrant colonization of the scalp by commensal Malassezia spp. is a major contributor in the multifactorial etiology of dandruff. Literature based understanding of Malassezia linked pathophysiology of dandruff allowed us to comprehend a strategy to potentiate the efficacy of a known antifungal agent used in dandruff therapy.

    The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.

    Source: Page


    Related Books